Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Journal of Research in Pharmacy 2023 , Vol 27 , Issue Supp.
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye DOI : 10.29228/jrp.500 The main reason why nano-sized drug delivery systems are approached with increasing interest in the field of science is to increase the therapeutic efficacy and reduce the incidence of side effects by enabling drugs to be targeted. With the advent of nanotechnology, many carrier systems - from inorganic based gold nanoparticles to organic based lipid or polymeric nanoparticles - have been designed and significant developments have been achieved in terms of their use in the treatment of various diseases thanks to intense scientific investments. However, these scientific developments in nanoscale drug delivery systems do not mean that there are definite treatment regimens for many diseases, especially cancer. Because, while any drug delivery system has many advantages, it also suffers from certain structural limitations. Therefore, novel and hybrid systems, defined as integrated systems, have been developed to highlight the advantages and overcome its limitations of each system. Based on this understanding, lipid polymer hybrid nanoparticles, combining liposomes and polymeric nanoparticles, emerged as a core shell structure in which the polymeric core is covered with a phospholipid layer. These integrated systems have attracted great interest in the academic community because they combine the biomimetic characteristics of liposomes and the architectural advantages of polymeric nanoparticles in their structures [1]. The general production techniques of this novel generation drug delivery nano-sized systems are categorized into two groups as single-step techniques and double-step techniques. Many physicochemical characterization controls such as drug loading, particle size, morphological properties, surface charge, drug release, lipid-shell thickness, interface chemical composition, lipid shell fluidity, and lipid shell transition analyses are used to characterize the core shell type lipid polymer hybrid nanoparticles. For in vitro biological characterization of these integrated systems, cellular uptake and cytotoxicity analyses are utilized as basic in vitro assays to assess effectiveness of drug encapsulated hybrid particles against target cells prior to in vivo evaluations [1,2]. Reviewing the applications of core shell type lipid polymer hybrid nanosystems in the field of biomedicine, it becomes clear that they play an important role in the treatment of various disorders, especially cancer [3,4]. Despite these technological advances in core shell type hybrid systems, there are still serious obstacles to their clinical use. The most serious of these is that the current laboratory-scale production methods used for their production are not suitable for scale-up. In order to overcome these limitations, it is necessary to develop production technologies that are suitable or adaptable for commercial production with a multidisciplinary approach and serious cooperation. Keywords : Core shell structure, lipid polymer hybrid nanocarriers, drug delivery
Marmara University